2025 HCPCS code J2502
(Active) Effective Date: N/A Revision Date: N/A Drugs - Injection Drugs, Administered by Injection Feed
Injection of 1 mg of long-acting pasireotide.
Modifiers may apply depending on the circumstances of service. Consult payer guidelines for specific modifier usage.
Pasireotide is medically necessary for patients with acromegaly or Cushing's disease when other standard therapies have failed to adequately control hormonal excess or alleviate associated symptoms.Documentation must support the failure of standard treatment.
Endocrinologists and other specialists managing pituitary disorders administer pasireotide when other treatments are unsuccessful. The clinical responsibility encompasses patient assessment, determining the appropriateness of pasireotide, administering the injection, and monitoring the patient's response to treatment, including potential side effects.
In simple words: This code is for a shot of a medicine called pasireotide, which helps with hormone problems.Doctors use this medicine when other treatments haven't worked.The code only covers the cost of the medicine itself, not the actual shot.
This HCPCS code, J2502, represents the administration of 1 mg of long-acting pasireotide via injection. Pasireotide is a medication that counteracts the abnormal effects of hormones produced in the pituitary gland.It's used in cases where other treatments or surgeries have proven ineffective.Common conditions treated with pasireotide include Cushing's disease (a form of Cushing syndrome) and acromegaly.The code solely covers the drug itself; separate codes are used for the administration procedure.
Example 1: A patient diagnosed with acromegaly, despite prior surgical intervention and medication, experiences persistent elevated growth hormone levels.The endocrinologist orders a course of long-acting pasireotide injections to manage the hormonal imbalances, using code J2502 for each 1mg dose., A patient with Cushing's disease exhibits symptoms despite medication management. The physician decides on long-acting pasireotide therapy. Code J2502 is used for the medication for each 1mg dose administered via injection., A patient with a rare form of pituitary adenoma unresponsive to conventional treatment presents with progressively worsening symptoms. The physician elects to initiate treatment with long-acting pasireotide via injection.Each 1mg dose is billed using code J2502.
* Diagnosis supporting the medical necessity of pasireotide (e.g., acromegaly, Cushing's disease).* Documentation of unsuccessful previous treatments or surgeries.* Complete record of medication administration, including date, time, dose, and route of administration.* Patient's response to the treatment and any side effects.
** This code represents only the drug and not the administration.Separate codes may be needed for the administration of the drug.Always verify payer coverage and coding guidelines prior to billing.
- Payment Status: Active
- Modifier TC rule: This code does not have a technical component (TC) modifier; the code represents only the drug.
- Specialties:Endocrinology
- Place of Service:Office, Hospital Inpatient, Hospital Outpatient